je.st
news
Home
› Athersys' MultiStem(R) Stem Cell Therapy Receives Orphan Drug Designation In Europe For Prevention Of Graft-Versus-Host Disease
Athersys' MultiStem(R) Stem Cell Therapy Receives Orphan Drug Designation In Europe For Prevention Of Graft-Versus-Host Disease
2013-12-30 06:10:10| drugdiscoveryonline Home Page
Athersys, Inc. (Nasdaq:ATHX) announced today that the Committee for Orphan Medicinal Products of the European Medicines Agency (EMA) has issued a positive opinion (EMA/OD/146/13) for the Company's allogeneic, multipotent adult progenitor cell, or MultiStem® therapy, for the prevention of graft-versus-host disease (GvHD)
Tags: europe
cell
drug
disease
Category:Biotechnology and Pharmaceuticals
Latest from this category |
All news |
||||||||||||||||||||
|
|
||||||||||||||||||||